Took a few notes when reading the paper[1], expanded some acronyms as well. Definitely a nice result, and an interesting paper.
* Steve Rosenberg's a respected expert in the field
* Adoptive T cell therapy (ACT) of TIL (tumor-infiltrating lymphocytes) T cells specific for a (common) KRAS mutation (G12D)
* Culture/expand TILs, use tandem-minigenes to narrow down most reactive (to in silico ID mutations) TILs, then use synthetic peptides on the mutations encoded in the TMG that elicits largest response to find which epitopes in particular were being reacted to.
* 6 tumors eradicated, 7th shrunk but recurred (had to be resected, patient has no disease 4 months later); 7th had lost the HLA-C allele that the TCRs were specific to
* The supplementary materials/methods were pretty interesting (very technical)
* Steve Rosenberg's a respected expert in the field
* Adoptive T cell therapy (ACT) of TIL (tumor-infiltrating lymphocytes) T cells specific for a (common) KRAS mutation (G12D)
* Culture/expand TILs, use tandem-minigenes to narrow down most reactive (to in silico ID mutations) TILs, then use synthetic peptides on the mutations encoded in the TMG that elicits largest response to find which epitopes in particular were being reacted to.
* 6 tumors eradicated, 7th shrunk but recurred (had to be resected, patient has no disease 4 months later); 7th had lost the HLA-C allele that the TCRs were specific to
* The supplementary materials/methods were pretty interesting (very technical)
[1] T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer http://www.nejm.org/doi/full/10.1056/NEJMoa1609279